Category - Executive Moves

Executive Moves

Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance

Liminal BioSciences (TSX:LMNL; OTCQX:LMNL) appointed Moira Daniels as the new head of regulatory affairs and quality assurance based at the company’s offices in Cambridge, UK. “Moira brings many years of global...

November 13, 2019

Executive Moves

Ventripoint names Justin Leushner as CEO

Ventripoint Diagnostics (TSXV:VPT; OTC:VPTDF) appointed Justin Leushner as CEO, replacing Dr. George Adams, who was elected chairman of the board. Mr. Leushner, who was named president of Ventripoint in September, has a...

November 4, 2019

Executive Moves

Orthofix appoints Jon Serbousek as president and CEO

Orthofix Medical (NASDAQ:OFIX) appointed Jon Serbousek as president, CEO and a director of its board, effective immediately. Mr. Serbousek succeeds Brad Mason, who previously announced his retirement. Mr. Mason has...

November 1, 2019

Executive Moves

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is internationally known for...

October 10, 2019

Executive Moves

Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to study the link...

October 10, 2019

Executive Moves

Zosano Pharma names Steven Lo as CEO

Zosano Pharma (NASDAQ:ZSAN) has appointed Steven Lo as president, CEO and a director, effective Oct. 21. Mr. Lo is departing from his role as CCO at Puma Biotechnology (NASDAQ:PUMA), effective Oct. 18, where he played a...

October 8, 2019

Executive Moves

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Canaccord Genuity appointed Edward Nash as its New York office’s managing director, equity research. Mr. Nash completes Canaccord Genuity’s team of five senior biotechnology analysts and will focus on companies...

October 7, 2019

Executive Moves

Cerecin names Lilian Chow as VP of clinical operations and regulatory affairs

Closely-held Cerecin appointed Lilian Chow as VP of clinical operations and regulatory affairs, responsible for leading Cerecin’s upcoming Phase 3 study of tricaprilin for the treatment of Alzheimer’s disease (AD). Ms...

October 7, 2019

Executive Moves

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...

October 3, 2019

Executive Moves

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell therapies and in...

September 30, 2019

Category - Executive Moves

Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance

Ventripoint names Justin Leushner as CEO

Orthofix appoints Jon Serbousek as president and CEO

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

Zosano Pharma names Steven Lo as CEO

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Cerecin names Lilian Chow as VP of clinical operations and regulatory affairs

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Follow Us

Subscribe

General

More

Subscribe